These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33518374)

  • 1. Prognostic Value of Serum Procalcitonin Levels in Patients With Febrile Neutropenia Presenting to the Emergency Department.
    Yadav S; Mathew R; Sahu AK; Jamshed N; Mohindra R; Aggarwal P; Batra A; Halder D; Brunda RL
    J Emerg Med; 2021 May; 60(5):641-647. PubMed ID: 33518374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia.
    Ahn S; Lee YS; Lim KS; Lee JL
    Support Care Cancer; 2013 Aug; 21(8):2303-8. PubMed ID: 23519568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of procalcitonin and lipopolysaccharide binding protein in cancer patients with chemotherapy-associated febrile neutropenia presenting to an emergency department.
    García de Guadiana-Romualdo L; Cerezuela-Fuentes P; Español-Morales I; Esteban-Torrella P; Jiménez-Santos E; Hernando-Holgado A; Albaladejo-Otón MD
    Biochem Med (Zagreb); 2019 Feb; 29(1):010702. PubMed ID: 30591812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.
    Ahn S; Rice TW; Yeung SJ; Cooksley T
    Support Care Cancer; 2018 May; 26(5):1465-1470. PubMed ID: 29168032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of procalcitonin in identifying high-risk cancer patients with febrile neutropenia: A useful alternative to the multinational association for supportive care in cancer score.
    Chaftari P; Chaftari AM; Hachem R; Yeung SJ; Dagher H; Jiang Y; Malek AE; Dailey Garnes N; Mulanovich VE; Raad I
    Cancer Med; 2021 Dec; 10(23):8475-8482. PubMed ID: 34725958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of complete blood count parameters to predict poor outcomes in cancer patients with febrile neutropenia presenting to the emergency department.
    Choi A; Park I; Lee HS; Chung J; Kim MJ; Park YS
    Ann Med; 2022 Dec; 54(1):599-609. PubMed ID: 35175159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department.
    Coyne CJ; Le V; Brennan JJ; Castillo EM; Shatsky RA; Ferran K; Brodine S; Vilke GM
    Ann Emerg Med; 2017 Jun; 69(6):755-764. PubMed ID: 28041827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10.
    Uys A; Rapoport BL; Fickl H; Meyer PW; Anderson R
    Eur J Cancer Care (Engl); 2007 Nov; 16(6):475-83. PubMed ID: 17944761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can Risk Stratification Tools Be Utilized to Safely Discharge Low-Risk Febrile Neutropenic Patients from the Emergency Department?
    Chen AY; Gottlieb M; Vilke GM; Coyne C
    J Emerg Med; 2023 Jan; 64(1):111-118. PubMed ID: 36641256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
    Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E
    Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CISNE versus MASCC: Identifying low risk febrile neutropenic patients.
    Mohindra R; Mathew R; Yadav S; Aggarwal P
    Am J Emerg Med; 2020 Nov; 38(11):2259-2263. PubMed ID: 31864874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic performance of adding patient-reported outcomes to the MASCC risk index to identify low-risk febrile neutropenia patients with solid tumors and lymphomas.
    Wang XJ; Goh DYT; Dorajoo SR; Chan A
    Support Care Cancer; 2017 Sep; 25(9):2815-2822. PubMed ID: 28401314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of febrile neutropenia in malignancy using the MASCC score and other factors: Feasibility and safety in routine clinical practice.
    Kumar P; Bajpai J; Shetty N; Medekar A; Kurkure PA; Ghadyalpatil N; Gupta S; Noronha V; Kanujia A; Parikh P; Banavali SD
    Indian J Cancer; 2014; 51(4):491-5. PubMed ID: 26842174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Modalities of management of cancer patients with febrile neutropenia in the oncology emergency unit of Gustave-Roussy and their related costs].
    Borget I; Antoun S; Chachaty E; Gachot B; Alibay A; Di Palma M; Merad M
    Bull Cancer; 2014 Oct; 101(10):925-31. PubMed ID: 25373692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can MASCC and CISNE scores predict delays of lung cancer chemotherapy after febrile neutropenia?
    Ono Y; Hayama N; Hattori S; Ito Y; Oguma T; Sakamaki F; Asano K
    Thorac Cancer; 2022 Dec; 13(24):3504-3509. PubMed ID: 36330990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: A systematic review and meta-analysis.
    Zheng B; Toarta C; Cheng W; Taljaard M; Reaume N; Perry JJ
    Crit Rev Oncol Hematol; 2020 May; 149():102922. PubMed ID: 32244162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms.
    Combariza JF; Lombana M; Pino LE; Arango M
    Support Care Cancer; 2015 Apr; 23(4):1009-13. PubMed ID: 25270848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study.
    Carmona-Bayonas A; Jiménez-Fonseca P; Virizuela Echaburu J; Antonio M; Font C; Biosca M; Ramchandani A; Martínez J; Hernando Cubero J; Espinosa J; Martínez de Castro E; Ghanem I; Beato C; Blasco A; Garrido M; Bonilla Y; Mondéjar R; Arcusa Lanza MÁ; Aragón Manrique I; Manzano A; Sevillano E; Castañón E; Cardona M; Gallardo Martín E; Pérez Armillas Q; Sánchez Lasheras F; Ayala de la Peña F
    J Clin Oncol; 2015 Feb; 33(5):465-71. PubMed ID: 25559804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of MASCC score in the inpatient management of febrile neutropenia: a single-center retrospective study.
    Bhardwaj PV; Emmich M; Knee A; Ali F; Walia R; Roychowdhury P; Clark J; Sridhar A; Lagu T; Loh KP
    Support Care Cancer; 2021 Oct; 29(10):5905-5914. PubMed ID: 33761002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective Evaluation of Multinational Association of Supportive Care in Cancer Risk Index Score for Gynecologic Oncology Patients With Febrile Neutropenia.
    Gunderson CC; Erickson BK; Wilkinson-Ryan I; Vesely SK; Leath CA; Gehrig PA; Moore KN
    Am J Clin Oncol; 2019 Feb; 42(2):138-142. PubMed ID: 30557164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.